Durvalumab Phase III Trial Could Change Mesothelioma Care
An international, much-anticipated phase III clinical trial that could change standard-of-care treatment for patients with malignant pleural mesothelioma will open soon, pending COVID-19 pandemic restrictions. The randomized trial will be studying the effectiveness of the immunotherapy drug durvalumab (Imfinzi) when used in combination with chemotherapy drugs pemetrexed (Alimta) and cisplatin for mesothelioma. Opening dates may vary by center because of the COVID-19 pandemic that has slowed or stalled clinical trials everywhere. Durvalumab produces an antibody that helps a patient’s own immune system kill tumor cells by negating the PD-L1 protein that often blocks it from happening. The protein typically allows tumor cells to avoid a patient’s immune system. Durvalumab, which is marketed as Imfinzi by the multinational biopharmaceutical company AstraZeneca, was approved by the FDA in 2017 for bladder cancer and has shown early effectiveness with certain lung cancers. The mesothelioma clinical trial, in a first-line setting for patients who are not surgical candidates, is known officially as DREAM3R. Patients will be randomized 2-to-1 to receive durvalumab with chemotherapy or standard chemotherapy alone. “We need more data to reach any conclusions,” trial investigator Dr. Bernardo Goulart at the Seattle Cancer Care Alliance told The Mesothelioma Center at Asbestos.com. “But earlier results have been promising. Chemotherapy with immunotherapy may...
Publication date: Available online 2 July 2020Source: Artificial Intelligence in MedicineAuthor(s): Jacques Bouaud, Sylvia Pelayo, Jean-Baptiste Lamy, Coralie Prebet, Charlotte Ngo, Luis Teixeira, Gilles Guézennec, Brigitte Seroussi
Conclusions: Operative laparoscopy under conscious sedation and local anesthesia appears to be a feasible technique in gynecologic surgery with no adverse patient outcomes. PMID: 32612345 [PubMed - in process]
CONCLUSION: recommendations emphasize isolation, proper rest, sleep, nutrition, hydration, medications, and in the more severe cases, oxygen support, monitoring of vital signs, emotional support, and multiprofessional and individualized care. Medications should be used with caution due to a lack of evidence. Future research is needed to analyze the impact of the infection at the beginning of pregnancy and the psychological aspects of pregnant women infected with the virus. PMID: 32609284 [PubMed - in process]
CONCLUSION: the number of infected patients will continue to increase. Chile needs to remain vigilant and adjust the strategies around the prevention and control measures. The behavior of the population plays a fundamental role. We suggest not relaxing restrictions and further improving epidemiological surveillance. Emergency preparations are needed and more resource elements need to be added to the current health support. This prediction is provisional and depends on keeping all intervening variables constant. Any alteration will modify the prediction. PMID: 32609283 [PubMed - in process]
CONCLUSION: the estimates of the transmission rate, epidemiological peak, and number of deaths from coronavirus in Brazilian metropolises presented expressive and important numbers the Brazilian Ministry of Health needs to consider. The results confirm the rapid spread of the virus and its high mortality in the country. PMID: 32609282 [PubMed - in process]
Abstract OBJECTIVE: to analyze the relationship between per capita income and the cumulative incidence of COVID-19 in the neighborhoods of the city of Rio de Janeiro, RJ, Brazil. METHOD: an ecological study using neighborhoods as units of analysis. The cumulative incidence rate per 100,000 inhabitants and the median of potential confounding variables (sex, race, and age) were calculated. Multiple analysis included quantile regression, estimating the regression coefficients of the variable income for every five percentiles from the 10th to 90th percentiles to verify the relationship between income and incidenc...
CONCLUSION: it became evident that palliative care in primary health care has been gradually developed, but it is necessary to consider the organization of primary health care and the social policies that support or weaken it, being considered a complex challenge. PMID: 32609270 [PubMed - in process]
Publication date: Available online 2 July 2020Source: Redox BiologyAuthor(s): Mengling Li, Chengai Wu, Jibran Sualeh Muhammad, Dan Yan, Koichi Tsuneyama, Hideki Hatta, Zheng-Guo Cui, Hidekuni Inadera
Publication date: Available online 2 July 2020Source: Medical Mycology Case ReportsAuthor(s): Théo Ghelfenstein Ferreira, Anastasia Saade, Alexandre Alanio, Stéphane Bretagne, Raffael Araujo de Castro, Samia Hamane, Elie Azoulay, Swann Bredin, Sarah Dellière
Publication date: Available online 26 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Sumanta Kar, Dinesh R. Katti, Kalpana S. Katti